Imanol Arozarena

Imanol Arozarena

UNVERIFIED PROFILE

Are you Imanol Arozarena?   Register this Author

Register author
Imanol Arozarena

Imanol Arozarena

Publications by authors named "Imanol Arozarena"

Are you Imanol Arozarena?   Register this Author

22Publications

443Reads

15Profile Views

Phenotype plasticity as enabler of melanoma progression and therapy resistance.

Nat Rev Cancer 2019 07 17;19(7):377-391. Epub 2019 Jun 17.

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41568-019-0154-4DOI Listing
July 2019

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.

Nat Commun 2018 09 5;9(1):3595. Epub 2018 Sep 5.

Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-Universidad de Cantabria, Santander, 39011, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-05941-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125387PMC
September 2018

Overcoming resistance to BRAF inhibitors.

Ann Transl Med 2017 Oct;5(19):387

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2017.06.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653517PMC
October 2017

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Cell Rep 2017 Aug;20(8):1818-1829

Department of Oncology, Navarrabiomed-Biomedical Research Centre, IdiSNA, 31008 Pamplona, Navarra, Spain; Division of Infection and Immunity, Rayne Institute, University College London, WC1E 6JF London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.07.075DOI Listing
August 2017

Targeting invasive properties of melanoma cells.

FEBS J 2017 07 1;284(14):2148-2162. Epub 2017 Mar 1.

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.14040DOI Listing
July 2017

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

J Exp Med 2017 06 27;214(6):1691-1710. Epub 2017 Apr 27.

Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20160855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460994PMC
June 2017

Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth.

Oncotarget 2017 May;8(20):32946-32959

Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Michael Smith Building, M13 9PT, Manchester, UK.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/16514
Publisher Site
http://dx.doi.org/10.18632/oncotarget.16514DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464841PMC
May 2017

Targeting MITF in the tolerance-phase.

Oncotarget 2016 08;7(34):54094-54095

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.9423DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342328PMC
August 2016

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.

Front Cell Dev Biol 2016 27;4:33. Epub 2016 Apr 27.

School of Applied Sciences, University of Huddersfield Huddersfield, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fcell.2016.00033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846800PMC
May 2016

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Cancer Cell 2016 Mar;29(3):270-284

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027PMC
March 2016

Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.

Pigment Cell Melanoma Res 2015 Jul 17;28(4):390-406. Epub 2015 Apr 17.

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692100PMC
July 2015

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.

Mol Cancer Ther 2015 May 16;14(5):1236-46. Epub 2015 Mar 16.

Manchester Cancer Research Centre, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0810DOI Listing
May 2015

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Mol Cancer 2014 Jun 19;13:154. Epub 2014 Jun 19.

Manchester Cancer Research Centre, The University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079649PMC
June 2014

Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.

J Natl Cancer Inst 2013 Jan 17;105(1):33-46. Epub 2012 Dec 17.

Molecular Cancer Studies, Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Oxford Rd, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536641PMC
January 2013

Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Genes Cancer 2011 Mar;2(3):182-94

Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC)-IDICAN-Universidad de Cantabria, Departamento de Biología Molecular, Facultad de Medicina, Cantabria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1947601911409213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128639PMC
March 2011

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Cancer Cell 2011 Jan 6;19(1):45-57. Epub 2011 Jan 6.

The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153561081000431
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2010.10.029DOI Listing
January 2011

Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins.

Mol Cell Biol 2009 Mar 29;29(5):1338-53. Epub 2008 Dec 29.

Departamento de Biología Molecular, Instituto de Biomedicina y Biotecnología de Cantabria, Consejo Superior de Investigaciones Científicas-IDICAN-Universidad de Cantabria, Santander, 39011 Cantabria, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.01359-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643815PMC
March 2009

Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors.

Mol Cell Biol 2004 Feb;24(4):1516-30

Instituto de Investigaciones Biomédicas, Consejo Superior de Investigaciones Científicas, Departamento de Biología Molecular, Unidad de Biomedicina de la Universidad de Cantabria-CSIC, Santander 39011, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC344182PMC
http://dx.doi.org/10.1128/mcb.24.4.1516-1530.2004DOI Listing
February 2004